Literature DB >> 23593080

STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer.

Yujuan Chen1, Jing Wang, Xiaodong Wang, Xuejuan Liu, Hongjiang Li, Qing Lv, Jingqiang Zhu, Bing Wei, Ying Tang.   

Abstract

PURPOSE: The aim of this study is to explore signal transducer and activator of transcription 3 (STAT3) expression in breast cancer and to analyze the detailed mechanism that STAT3 contributes to the progression of breast cancer.
METHODS: We retrospectively analyzed the clinicopathologic characteristics and overall survival (OS) of 140 breast cancer patients after curative surgery, and detected STAT3 expression, phosphorylated STAT3 (pSTAT3) expression, Ki-67 expression, vascular endothelial growth factor (VEGF)-C and -D expression in breast cancer tissues, and adjacent nontumor tissues. Survival analysis and relationship analysis were adopted for demonstrated the important mechanism of STAT3 contribution to progression of breast cancer.
RESULTS: STAT3 expression, pSTAT3 expression, Ki-67 expression, VEGF-C expression, and VEGF-D expression in breast cancer tissues were significantly higher than those in adjacent nontumor tissues, respectively. With survival analysis, only number of lymph node metastasis (N stage) was identified as the independent predictors of the OS of breast cancer patients. Besides, we demonstrated there was the most prominent correlation between STAT3 expression and lymph node metastasis in breast cancer tissues by using the multinominal regression method.
CONCLUSION: STAT3, a poor survival biomarker potential association with lymph node metastasis, was suitable for predication the OS of breast cancer patients after curative resection.

Entities:  

Keywords:  Breast neoplasms; Neoplasm metastasis; Prognosis; STAT3 transcription factor

Year:  2013        PMID: 23593080      PMCID: PMC3625768          DOI: 10.4048/jbc.2013.16.1.40

Source DB:  PubMed          Journal:  J Breast Cancer        ISSN: 1738-6756            Impact factor:   3.588


  27 in total

1.  Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT.

Authors:  Pamela Cowin; Danny R Welch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-09       Impact factor: 2.673

2.  STAT3 negatively regulates thyroid tumorigenesis.

Authors:  Joana Pinto Couto; Laura Daly; Ana Almeida; Jeffrey A Knauf; James A Fagin; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares; David Lyden; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

3.  Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.

Authors:  Bronislaw Pytowski; Jeremy Goldman; Kris Persaud; Yan Wu; Larry Witte; Daniel J Hicklin; Mihaela Skobe; Kendrick C Boardman; Melody A Swartz
Journal:  J Natl Cancer Inst       Date:  2005-01-05       Impact factor: 13.506

4.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

5.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

6.  The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.

Authors:  Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

7.  Activated stat-3 in melanoma.

Authors:  Jane L Messina; Hua Yu; Adam I Riker; Pamela N Munster; Richard L Jove; Adil I Daud
Journal:  Cancer Control       Date:  2008-07       Impact factor: 3.302

Review 8.  Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis.

Authors:  Anna Glechner; Achim Wöckel; Gerald Gartlehner; Kylie Thaler; Michaela Strobelberger; Ursula Griebler; Rolf Kreienberg
Journal:  Eur J Cancer       Date:  2012-10-17       Impact factor: 9.162

9.  Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis.

Authors:  Philippe O Van Trappen; Dawn Steele; David G Lowe; Suhail Baithun; Nigel Beasley; Wilko Thiele; Herbert Weich; Jaya Krishnan; John H Shepherd; Michael S Pepper; David G Jackson; Jonathan P Sleeman; Ian J Jacobs
Journal:  J Pathol       Date:  2003-12       Impact factor: 7.996

10.  Expression of STAT3, MMP-1 and TIMP-1 in gastric cancer and correlation with pathological features.

Authors:  Qin-Wei Cai; Jun Li; Xue-Qin Li; Jian-Qiang Wang; Yuan Huang
Journal:  Mol Med Rep       Date:  2012-03-27       Impact factor: 2.952

View more
  31 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.

Authors:  Ling Zhao; Qingyuan Zhang; Xin Luan; Xu Huang; Shu Zhao; Hong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell.

Authors:  Jingyu Deng; Jingli Cui; Nan Jiang; Rupeng Zhang; Li Zhang; Xishan Hao; Han Liang
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

4.  Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.

Authors:  Vivian Wai Yan Lui; Noah D Peyser; Patrick Kwok-Shing Ng; Jozef Hritz; Yan Zeng; Yiling Lu; Hua Li; Lin Wang; Breean R Gilbert; Ignacio J General; Ivet Bahar; Zhenlin Ju; Zhenghe Wang; Kelsey P Pendleton; Xiao Xiao; Yu Du; John K Vries; Peter S Hammerman; Levi A Garraway; Gordon B Mills; Daniel E Johnson; Jennifer R Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

5.  Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer.

Authors:  L I Yan; L I Li; Qinghuai Li; Wang DI; Wei Shen; Linlei Zhang; Hao Guo
Journal:  Exp Ther Med       Date:  2015-04-07       Impact factor: 2.447

Review 6.  Critical roles of non-histone protein lysine methylation in human tumorigenesis.

Authors:  Ryuji Hamamoto; Vassiliki Saloura; Yusuke Nakamura
Journal:  Nat Rev Cancer       Date:  2015-02       Impact factor: 60.716

7.  STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes.

Authors:  Haishan Zhao; Zhe Wang; Huizhe Wu; Qinghuan Xiao; Weifan Yao; Enhua Wang; Yong Liu; Minjie Wei
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

8.  Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.

Authors:  Hongyu Kong; Qiongwen Zhang; Yunhui Zeng; Hong Wang; Mengqian Wu; Tianying Zheng; Yanzhang Zeng; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Suppressor of cytokine signaling 1 inhibits the maturation of dendritic cells involving the nuclear factor kappa B signaling pathway in the glioma microenvironment.

Authors:  M He; X Chen; M Luo; L Ouyang; L Xie; Z Huang; A Liu
Journal:  Clin Exp Immunol       Date:  2020-06-30       Impact factor: 4.330

Review 10.  Interleukin-6 induces drug resistance in renal cell carcinoma.

Authors:  Kei Ishibashi; Tomoyuki Koguchi; Kanako Matsuoka; Akifumi Onagi; Ryo Tanji; Ruriko Takinami-Honda; Seiji Hoshi; Mitsutaka Onoda; Yoshimasa Kurimura; Junya Hata; Yuichi Sato; Masao Kataoka; Soichiro Ogawsa; Nobuhiro Haga; Yoshiyuki Kojima
Journal:  Fukushima J Med Sci       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.